Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Trulicity Cardiovascular Data (REWIND Trial) The REWIND trial studied dulaglutide in patients with Type 2 diabetes: Study population: 9,901 patients with Type 2 diabetes, broader population including those without prior cardiovascular events Results: 12% reduction in major adverse cardiovascular events (MACE) Statistically significant cardiovascular protection Benefit seen in both primary and secondary prevention Ozempic Cardiovascular Data (SUSTAIN 6 and SELECT) SUSTAIN 6 trial (diabetes population): 26% reduction in MACE in patients with Type 2 diabetes and high cardiovascular risk Significant cardiovascular protection SELECT trial (obesity population): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied for cardiovascular outcomes regardless of diabetes status Cardiovascular Comparison Both medications provide cardiovascular protection
Data reveal that early non-responders receiving phentermine achieved 5.9% weight loss compared to just 2.8% with placebo after 24 weeks, with over half reaching the clinically meaningful threshold of 5% weight reduction
London: Pharmaceutical Press
Contrave : What are the similarities
US$ 27.05
US$ 21.20
US$ 23.94
US$ 23.75
US$ 23.29
US$ 27.36
